請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50440完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 阮雪芬(Hsueh-Fen Juan) | |
| dc.contributor.author | Chun-Li Hou | en |
| dc.contributor.author | 侯君里 | zh_TW |
| dc.date.accessioned | 2021-06-15T12:40:51Z | - |
| dc.date.available | 2021-08-02 | |
| dc.date.copyright | 2016-08-02 | |
| dc.date.issued | 2016 | |
| dc.date.submitted | 2016-07-27 | |
| dc.identifier.citation | Adhikary S, Eilers M (2005) Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6: 635-645
Al-Tonbary Y, Badr M, Mansour A, El Safy U, Saeed S, Hassan T, Elashery R, Nofal R, Darwish A (2015) Clinico-epidemiology of neuroblastoma in north east Egypt: A 5-year multicenter study. Oncol Lett 10: 1054-1062 Andrews PD (2005) Aurora kinases: shining lights on the therapeutic horizon? Oncogene 24: 5005-5015 Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29 Berenson RJ, Bensinger WI, Hill RS, Andrews RG, Garcia-Lopez J, Kalamasz DF, Still BJ, Spitzer G, Buckner CD, Bernstein ID, et al. (1991) Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 77: 1717-1722 Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, Simon T, Hero B (2005) Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 6: 649-658 Blackwood EM, Eisenman RN (1991) Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251: 1211-1217 Bogenmann E, Torres M, Matsushima H (1995) Constitutive N-myc gene expression inhibits trkA mediated neuronal differentiation. Oncogene 10: 1915-1925 Brodersen DE, Nissen P (2005) The social life of ribosomal proteins. The FEBS journal 272: 2098-2108 Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216 Burkhart CA, Cheng AJ, Madafiglio J, Kavallaris M, Mili M, Marshall GM, Weiss WA, Khachigian LM, Norris MD, Haber M (2003) Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst 95: 1394-1403 Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P (2008) Drug target identification using side-effect similarity. Science 321: 263-266 Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene 23: 2825-2837 Chang YT, Chang MC, Su TC, Liang PC, Su YN, Kuo CH, Wei SC, Wong JM (2009) Lipoprotein lipase mutation S447X associated with pancreatic calcification and steatorrhea in hyperlipidemic pancreatitis. Journal of clinical gastroenterology 43: 591-596 Chen SS, Chang PC, Cheng YW, Tang FM, Lin YS (2002) Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO J 21: 4491-4499 Cheung NK, Dyer MA (2013) Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 13: 397-411 Choi YB, Bae GE, Lee NH, Kim JS, Lee SH, Yoo KH, Sung KW, Koo HH (2015) Clinical Significance of Persistent Tumor in Bone Marrow during Treatment of High-risk Neuroblastoma. J Korean Med Sci 30: 1062-1067 Cox J, Mann M (2011) Quantitative, high-resolution proteomics for data-driven systems biology. Annu Rev Biochem 80: 273-299 Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W (2010) Aurora kinase inhibitors--rising stars in cancer therapeutics? Mol Cancer Ther 9: 268-278 Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A et al (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954 Delezie J, Dumont S, Dardente H, Oudart H, Grechez-Cassiau A, Klosen P, Teboul M, Delaunay F, Pevet P, Challet E (2012) The nuclear receptor REV-ERBalpha is required for the daily balance of carbohydrate and lipid metabolism. FASEB J 26: 3321-3335 DiMasi JA, Hansen RW, Grabowski HG, Lasagna L (1991) Cost of innovation in the pharmaceutical industry. J Health Econ 10: 107-142 Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, Taylor SS (2003) Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161: 267-280 Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bloch CA, Castle VP (1994) Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54: 3253-3259 Dudley JT, Deshpande T, Butte AJ (2011) Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform 12: 303-311 Egeberg O (1965) Inherited Antithrombin Deficiency Causing Thrombophilia. Thrombosis et diathesis haemorrhagica 13: 516-530 Eisenberg S, Rachmilewitz D (1975) Interaction of rat plasma very low density lipoprotein with lipoprotein lipase-rich (postheparin) plasma. J Lipid Res 16: 341-351 Ferreira LD, Pulawa LK, Jensen DR, Eckel RH (2001) Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance. Diabetes 50: 1064-1068 Field MS, Szebenyi DM, Stover PJ (2006) Regulation of de novo purine biosynthesis by methenyltetrahydrofolate synthetase in neuroblastoma. J Biol Chem 281: 4215-4221 Friedman GK, Castleberry RP (2007) Changing trends of research and treatment in infant neuroblastoma. Pediatr Blood Cancer 49: 1060-1065 Fritsch P, Kerbl R, Lackner H, Urban C (2004) 'Wait and see' strategy in localized neuroblastoma in infants: an option not only for cases detected by mass screening. Pediatr Blood Cancer 43: 679-682 Fu J, Bian M, Jiang Q, Zhang C (2007) Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 5: 1-10 Gehrisch S (1999) Common mutations of the lipoprotein lipase gene and their clinical significance. Curr Atheroscler Rep 1: 70-78 Gene Ontology C (2015) Gene Ontology Consortium: going forward. Nucleic Acids Res 43: D1049-1056 Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680 Grovas A, Fremgen A, Rauck A, Ruymann FB, Hutchinson CL, Winchester DP, Menck HR (1997) The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer 80: 2321-2332 Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL (1997) Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 19: 428-432 Gurwitz D, Cunningham DD (1990) Neurite outgrowth activity of protease nexin-1 on neuroblastoma cells requires thrombin inhibition. Journal of cellular physiology 142: 155-162 Han CL, Chien CW, Chen WC, Chen YR, Wu CP, Li H, Chen YJ (2008) A multiplexed quantitative strategy for membrane proteomics: opportunities for mining therapeutic targets for autosomal dominant polycystic kidney disease. Mol Cell Proteomics 7: 1983-1997 Hansford LM, Thomas WD, Keating JM, Burkhart CA, Peaston AE, Norris MD, Haber M, Armati PJ, Weiss WA, Marshall GM (2004) Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci U S A 101: 12664-12669 Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10: 262-267 Hoehner JC, Gestblom C, Hedborg F, Sandstedt B, Olsen L, Pahlman S (1996) A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage. Lab Invest 75: 659-675 Holland EC (2004) Regulation of translation and cancer. Cell Cycle 3: 452-455 Huang da W, Sherman BT, Lempicki RA (2009a) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13 Huang da W, Sherman BT, Lempicki RA (2009b) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57 Huey PU, Waugh KC, Etienne J, Eckel RH (2002) Lipoprotein lipase is expressed in rat sciatic nerve and regulated in response to crush injury. J Lipid Res 43: 19-25 Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, Murino L, Tagliaferri R, Brunetti-Pierri N, Isacchi A, di Bernardo D (2010) Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 107: 14621-14626 Jeng YM, Peng SY, Lin CY, Hsu HC (2004) Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10: 2065-2071 Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, Bork P, von Mering C (2009) STRING 8--a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 37: D412-416 Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501: 346-354 Kajstura M, Halicka HD, Pryjma J, Darzynkiewicz Z (2007) Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete 'sub-G1' peaks on DNA content histograms. Cytometry A 71: 125-131 Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM et al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132 Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK (2002) Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 23: 967-975 Kasai H, Nadano D, Hidaka E, Higuchi K, Kawakubo M, Sato TA, Nakayama J (2003) Differential expression of ribosomal proteins in human normal and neoplastic colorectum. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 51: 567-574 Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KL, Edwards DD, Shoichet BK, Roth BL (2009) Predicting new molecular targets for known drugs. Nature 462: 175-181 Kim DW, Jo YH, Kim JH, Wu HG, Rhee CS, Lee CH, Kim TY, Heo DS, Bang YJ, Kim NK (2004) Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. Cancer 101: 2257-2260 Kim HT, Kim KP, Lledias F, Kisselev AF, Scaglione KM, Skowyra D, Gygi SP, Goldberg AL (2007) Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages. J Biol Chem 282: 17375-17386 Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, Kako Y, Velez-Carrasco W, Goldberg IJ, Breslow JL, Shulman GI (2001) Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 98: 7522-7527 Kota RS, Ramana CV, Tenorio FA, Enelow RI, Rutledge JC (2005) Differential effects of lipoprotein lipase on tumor necrosis factor-alpha and interferon-gamma-mediated gene expression in human endothelial cells. J Biol Chem 280: 31076-31084 Kreunin P, Yoo C, Urquidi V, Lubman DM, Goodison S (2007) Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model. Proteomics 7: 299-312 Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung NK (2013) Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. Cancer 119: 665-671 Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935 Lastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C, Roberts P, Hall AG, Tweddle DA, Pearson AD, Lewis I, Burchill SA, Jackson MS (2007) Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 26: 7432-7444 Lau DT, Flemming CL, Gherardi S, Perini G, Oberthuer A, Fischer M, Juraeva D, Brors B, Xue C, Norris MD, Marshall GM, Haber M, Fletcher JI, Ashton LJ (2015) MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma. Oncotarget 6: 15510-15523 Lexander H, Palmberg C, Auer G, Hellstrom M, Franzen B, Jornvall H, Egevad L (2005) Proteomic analysis of protein expression in prostate cancer. Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 27: 263-272 Lin WT, Hung WN, Yian YH, Wu KP, Han CL, Chen YR, Chen YJ, Sung TY, Hsu WL (2006) Multi-Q: a fully automated tool for multiplexed protein quantitation. J Proteome Res 5: 2328-2338 London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, Matthay KK (2011) Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol 29: 3286-3292 Luo J, Su F, Chen D, Shiloh A, Gu W (2000) Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408: 377-381 Maggi LB, Jr., Weber JD (2005) Nucleolar adaptation in human cancer. Cancer investigation 23: 599-608 Mao X, Seidlitz E, Truant R, Hitt M, Ghosh HP (2004) Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth. Oncogene 23: 5632-5642 Marcu KB, Bossone SA, Patel AJ (1992) myc function and regulation. Annu Rev Biochem 61: 809-860 Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362: 2202-2211 Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369: 2106-2120 Maris JM, Matthay KK (1999) Molecular biology of neuroblastoma. J Clin Oncol 17: 2264-2279 Matthay KK, O'Leary MC, Ramsay NK, Villablanca J, Reynolds CP, Atkinson JB, Haase GM, Stram DO, Seeger RC (1995) Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer 31A: 572-575 Mattila PK, Lappalainen P (2008) Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol 9: 446-454 Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP (1999) Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 91: 1138-1146 McMahon SB (2008) Control of nucleotide biosynthesis by the MYC oncoprotein. Cell Cycle 7: 2275-2276 Mead JR, Irvine SA, Ramji DP (2002) Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl) 80: 753-769 Michaelis M, Selt F, Rothweiler F, Loschmann N, Nusse B, Dirks WG, Zehner R, Cinatl J, Jr. (2014) Aurora kinases as targets in drug-resistant neuroblastoma cells. PLoS One 9: e108758 Miller AL, Smith LC (1973) Activation of lipoprotein lipase by apolipoprotein glutamic acid. Formation of a stable surface film. J Biol Chem 248: 3359-3362 Morton CL, Houghton PJ (2007) Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2: 247-250 Mountzios G, Terpos E, Dimopoulos MA (2008) Aurora kinases as targets for cancer therapy. Cancer Treat Rev 34: 175-182 Muller P, Langenbach A, Kaminski A, Rychly J (2013) Modulating the actin cytoskeleton affects mechanically induced signal transduction and differentiation in mesenchymal stem cells. PLoS One 8: e71283 Nilsson R, Jain M, Madhusudhan N, Sheppard NG, Strittmatter L, Kampf C, Huang J, Asplund A, Mootha VK (2014) Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nature communications 5: 3128 Okubo M, Horinishi A, Saito M, Ebara T, Endo Y, Kaku K, Murase T, Eto M (2007) A novel complex deletion-insertion mutation mediated by Alu repetitive elements leads to lipoprotein lipase deficiency. Mol Genet Metab 92: 229-233 Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL (2006) Global mapping of pharmacological space. Nat Biotechnol 24: 805-815 Paradis E, Clement S, Julien P, Ven Murthy MR (2003) Lipoprotein lipase affects the survival and differentiation of neural cells exposed to very low density lipoprotein. J Biol Chem 278: 9698-9705 Paradis E, Julien P, Ven Murthy MR (2004) Requirement for enzymatically active lipoprotein lipase in neuronal differentiation: a site-directed mutagenesis study. Brain Res Dev Brain Res 149: 29-37 Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D, European Neuroblastoma Study G, Children's C, Leukaemia G (2008) High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 9: 247-256 Piskareva O, Harvey H, Nolan J, Conlon R, Alcock L, Buckley P, Dowling P, Henry M, O'Sullivan F, Bray I, Stallings RL (2015) The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro. Cancer Lett 364: 142-155 Postuma RB, Martins RN, Cappai R, Beyreuther K, Masters CL, Strickland DK, Mok SS, Small DH (1998) Effects of the amyloid protein precursor of Alzheimer's disease and other ligands of the LDL receptor-related protein on neurite outgrowth from sympathetic neurons in culture. FEBS Lett 428: 13-16 Puder M, Barnard GF, Staniunas RJ, Steele GD, Jr., Chen LB (1993) Nucleotide and deduced amino acid sequence of human ribosomal protein L18. Biochim Biophys Acta 1216: 134-136 Ramsay G, Stanton L, Schwab M, Bishop JM (1986) Human proto-oncogene N-myc encodes nuclear proteins that bind DNA. Mol Cell Biol 6: 4450-4457 Rappsilber J, Mann M, Ishihama Y (2007) Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2: 1896-1906 Rasmuson A, Segerstrom L, Nethander M, Finnman J, Elfman LH, Javanmardi N, Nilsson S, Johnsen JI, Martinsson T, Kogner P (2012) Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. PLoS One 7: e51297 Richmond A, Su Y (2008) Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech 1: 78-82 Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ (2004) Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3: 1154-1169 Ruggero D, Pandolfi PP (2003) Does the ribosome translate cancer? Nat Rev Cancer 3: 179-192 Schiavetti A, Foco M, Chiriaco D, Iacobini M, Varrasso G, Ingrosso A, Conti L (2010) Venous thrombosis and procoagulant factors in high-risk neuroblastoma. J Pediatr Hematol Oncol 32: 93-96 Schleiermacher G, Janoueix-Lerosey I, Delattre O (2014) Recent insights into the biology of neuroblastoma. Int J Cancer 135: 2249-2261 Schramm G, Wiesberg S, Diessl N, Kranz AL, Sagulenko V, Oswald M, Reinelt G, Westermann F, Eils R, Konig R (2010) PathWave: discovering patterns of differentially regulated enzymes in metabolic pathways. Bioinformatics 26: 1225-1231 Schwab M (2004) MYCN in neuronal tumours. Cancer Lett 204: 179-187 Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305: 245-248 Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116 Seegers WH, Johnson JF, Fell C (1954) An antithrombin reaction to prothrombin activation. Am J Physiol 176: 97-103 Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504 Silva A, Wang J, Lomahan S, Tran TA, Grenlin L, Suganami A, Tamura Y, Ikegaki N (2014) Aurora kinase A is a possible target of OSU03012 to destabilize MYC family proteins. Oncol Rep 32: 901-905 Sjostrom SK, Finn G, Hahn WC, Rowitch DH, Kenney AM (2005) The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell 9: 327-338 Slack A, Lozano G, Shohet JM (2005) MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Cancer Lett 228: 21-27 Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, Smith FO, Reaman GH (2010) Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28: 2625-2634 Sun H, Wang Y, Wang Z, Meng J, Qi Z, Yang G (2014) Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks. Biochim Biophys Acta 1843: 934-944 Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6: 529-535 van Riggelen J, Yetil A, Felsher DW (2010) MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer 10: 301-309 Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033 Varan A, Kesik V, Senocak ME, Kale G, Akyuz C, Buyukpamukcu M (2015) The efficacy of delayed surgery in children with high-risk neuroblastoma. J Cancer Res Ther 11: 268-271 Vervoorts J, Luscher-Firzlaff J, Luscher B (2006) The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem 281: 34725-34729 von Mering C, Jensen LJ, Snel B, Hooper SD, Krupp M, Foglierini M, Jouffre N, Huynen MA, Bork P (2005) STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res 33: D433-437 Wang B, Hsu SH, Frankel W, Ghoshal K, Jacob ST (2012) Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology 56: 186-197 Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16: 2985-2995 Wilkins MR, Pasquali C, Appel RD, Ou K, Golaz O, Sanchez JC, Yan JX, Gooley AA, Hughes G, Humphery-Smith I, Williams KL, Hochstrasser DF (1996) From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (N Y) 14: 61-65 Wilson DN, Nierhaus KH (2005) Ribosomal proteins in the spotlight. Critical reviews in biochemistry and molecular biology 40: 243-267 Winter GE, Rix U, Lissat A, Stukalov A, Mullner MK, Bennett KL, Colinge J, Nijman SM, Kubicek S, Kovar H, Kontny U, Superti-Furga G (2011) An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B. Mol Cancer Ther 10: 1846-1856 Wool IG, Chan YL, Gluck A (1995) Structure and evolution of mammalian ribosomal proteins. Biochemistry and cell biology = Biochimie et biologie cellulaire 73: 933-947 Wu YH, Hu CW, Chien CW, Chen YJ, Huang HC, Juan HF (2013) Quantitative proteomic analysis of human lung tumor xenografts treated with the ectopic ATP synthase inhibitor citreoviridin. PLoS One 8: e70642 Yin ET, Wessler S, Stoll PJ (1971) Identity of plasma-activated factor X inhibitor with antithrombin 3 and heparin cofactor. J Biol Chem 246: 3712-3719 Yu Y, Maggi LB, Jr., Brady SN, Apicelli AJ, Dai MS, Lu H, Weber JD (2006) Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol 26: 3798-3809 Zhou X, Hao Q, Liao JM, Liao P, Lu H (2013) Ribosomal protein S14 negatively regulates c-Myc activity. J Biol Chem 288: 21793-21801 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50440 | - |
| dc.description.abstract | 舊藥新用為較具有投資價值的藥物開發模式，能有效的提供治療疾病藥物的選擇。神經母細胞瘤是胚胎發育過程中因交感神經分化失敗而形成的惡性腫瘤，此癌症好發於五歲以下的兒童，是孩童常見的第三種癌症，且此癌症致死率高達五成。由於此癌症中高危險群的病患，目前可選擇使用的藥物非常少，因此尋找治療惡性神經母細胞瘤用藥，是一個急需的課題。本篇研究中我們藉由分析美國國家衛生研究院所提供的資料庫(Library of Integrated Network-based Cellular Signatures, LINCS)，參考現今於臨床上，治療神經母細胞瘤的用藥，比對資料庫中上千種的小分子藥物，篩選高相似性的藥物，為後續生物實驗測試。於分析結果中發現，陶扎色替(Tozasertib)和臨床用藥截剋瘤(Crizotinib)具有高度的相似性。我們更進一步使用網路藥物資料庫(Genomics of Drug Sensitivity in Cancer database, GDSC)，發現陶扎色替具有更低的IC50，及表示毒殺性效果更好。接下來我們藉由細胞實驗來驗證藥物的胞殺性，還有相關細胞生理功能的影響，包含導致細胞週期停滯、細胞聚落能力降低及細胞轉移侵襲能力變弱。再來使用兩種動物實驗模型，包含異體移植腫瘤老鼠模型(xenograft mouse model)及轉基因老鼠模型(transgenic mouse model)，更再進一步確定藥物於活體上的藥效。於兩種實驗動物的結果可顯示，藥效作用均可有效抑制腫瘤生長的能力，並且對於動物存活能力也有顯著的提升。最後經由相對和絕對定量等量異位標籤技術(Isobaric Tags for Relative and Absolute Quantitation, iTRAQ)，並以蛋白質體學，來探討陶扎色替的藥效作用機制為何。我們於異體移植腫瘤和轉基因老鼠模型分別定量了2,912個和2,255個蛋白質，並分別挑選出在異體移植腫瘤和轉基因老鼠模型有顯著表現差異的105個和150個蛋白質。於這兩種不同的老鼠模型中，我們使用生物資訊學方法分析表現量有顯著差異的蛋白質，均發現它們多與細胞骨架的調控有關，顯示陶扎色替會影響細胞轉移和侵襲能力。根據此研究結果，指出陶扎色替對於神經母細胞瘤有良好的抑制效果，因此我們希望此研究能夠提供未來高危險群Mycn-增生的神經母細胞瘤一個新的治療策略。 | zh_TW |
| dc.description.provenance | Made available in DSpace on 2021-06-15T12:40:51Z (GMT). No. of bitstreams: 1 ntu-105-R03b43011-1.pdf: 10184859 bytes, checksum: 088b8be3336ce78ed5144b31a9023cf6 (MD5) Previous issue date: 2016 | en |
| dc.description.tableofcontents | 謝辭 i
中文摘要 iii Abstract v Contents vii List of Figures x List of Tables xiii Abbreviation xiv Chapter 1 Introduction 1 1.1 Neuroblastoma 1 1.2 MYCN 2 1.3 Drug discovery 4 1.4 An Aurora kinase inhibitor: tozasertib 5 1.5 Proteomics 6 1.6 Motivation 7 Chapter 2 Materials and Methods 9 2.1 Experimental design 9 2.2 Perturbation similarity analysis 10 2.3 Cell culture 10 2.4 Drug treatment 11 2.5 Cell viability assay using MTS assay 11 2.6 Colony formation assay 11 2.7 DNA content analysis 12 2.8 Flow cytometric analysis of apoptosis using Annexin V-FITC/PI staining 13 2.9 Animal efficacy studies 13 2.10 Tumor protein preparation 15 2.11 Reduction, alkylation, and digestion of proteins 15 2.12 iTRAQ labeling of peptides 16 2.13 Strong cation exchange (SCX) chromatography 17 2.14 StageTip desalting 17 2.15 ZipTip desalting 18 2.16 LC-MS/MS analysis 18 2.17 Protein identification and quantification 20 2.18 Selection of differentially expressed proteins 21 2.19 Functional enrichment analysis and association network 22 2.20 Western blotting 22 2.21 Transwell migration and invasion assay 23 2.22 Statistical analysis 24 Chapter 3 Results 25 3.1 Drug repurposing via perturbation similarity analysis 25 3.2 Tozasertib causes cytotoxicity of neuroblastoma cell lines 25 3.3 Tozasertib reduces proliferation of neuroblastoma cell lines 26 3.4 Tozasertib induces G2/M phase arrest in neuroblastoma cell lines 26 3.5 Tozasertib induces apoptosis in neuroblastoma cell lines 27 3.6 Tozasertib has anti-cancer effect on neuroblastoma xenograft mice 28 3.7 Tozasertib has anti-cancer effect in neuroblastoma transgenic mice 29 3.8 Proteomic analysis identifies changes with tozasertib treatment in small-scale experiments 30 3.9 Proteomic analysis identifies changes with tozasertib treatment in large-scale experiments 32 3.10 Functional analysis of proteomic data 33 3.11 Tozasertib reduces metastasis of neuroblastoma cell lines 34 3.12 Pathway enrichment analysis of proteomic data 35 Chapter 4 Discussion 37 Chapter 5 Future work 46 Chapter 6 References 48 Figures 59 Tables 106 Appendix 131 | |
| dc.language.iso | en | |
| dc.title | 探討泛極光激酶抑制劑tozasertib於Mycn擴增之神經母細胞瘤的舊藥新用潛力 | zh_TW |
| dc.title | The pan-Aurora kinase inhibitor tozasertib as a repurposed drug for Mycn-amplified neuroblastoma | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 104-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 黃宣誠(Hsuan-Cheng Huang),黃敏銓(Min-Chuan Huang),許文明(Wen-Ming Hsu) | |
| dc.subject.keyword | 惡性,Mycn基因擴增,神經母細胞瘤,陶扎色替,舊藥新用,蛋白質體學,相對和絕對定量等量異位標籤技術, | zh_TW |
| dc.subject.keyword | high-risk,Mycn-amplified,neuroblastoma,tozasertib,drug repurposing,proteomics,iTRAQ, | en |
| dc.relation.page | 135 | |
| dc.identifier.doi | 10.6342/NTU201601400 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2016-07-28 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 分子與細胞生物學研究所 | zh_TW |
| 顯示於系所單位： | 分子與細胞生物學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-105-1.pdf 目前未授權公開取用 | 9.95 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。